Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.35 |
| ▸ | ACACB | O00763 | 8/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | PPIA | P62937 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744057 | 0.83 | F2 (0.40) | PDCD1CD274ACACBPTGER1FNTA | |
| SCHEMBL6596215 | 0.81 | MRGPRX4 (0.37) | PDCD1CD274MRGPRX4PTGER1FNTA | |
| SCHEMBL6738071 | 0.80 | MRGPRX4 (0.36) | PDCD1CD274MRGPRX4ACACBPTGER1 | |
| SCHEMBL6593252 | 0.76 | MRGPRX4 (0.36) | PDCD1CD274MRGPRX4PTGER1FNTA | |
| SCHEMBL7407522 | 0.75 | MRGPRX4 (0.41) | MRGPRX4PTGER1PPIASLC6A9CYP19A1 | |
| SCHEMBL6581757 | 0.75 | MRGPRX4 (0.46) | MRGPRX4PTGER1 | |
| SCHEMBL6591621 | 0.75 | MRGPRX4 (0.39) | PDCD1CD274MRGPRX4PTGER1PPIA | |
| SCHEMBL7482624 | 0.74 | PTGER1 (0.38) | MRGPRX4PTGER1PPIASLC6A9CYP19A1 | |
| SCHEMBL6589872 | 0.74 | MRGPRX4 (0.38) | MRGPRX4PTGER1PPIASLC6A9CYP19A1 | |
| SCHEMBL6163649 | 0.74 | MRGPRX4 (0.42) | MRGPRX4PTGER1PPIASLC6A9CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686367-B2 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030149040-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2003-08-07 | — | — | US | disclosed |
| US-6552030-B2 | Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine | BERLEX LABORATORIES, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6495684-B2 | INHIBIT HUMAN FACTOR XA; TREATING DISEASES CHARACTERIZED BY THROMBOTIC ACTIVITY; FOR EXAMPLE 3-((3,5-DIFLUORO-6-(3-(1-METHYLIMIDAZOLIN-2-YL)PHENOXY)-4-(2,3 -DIHYDROXYPROPOXY)PYRIDIN-2-YL)OXY)-4-HYDROXYBENZAMIDINE | BERLEX LABORATORIES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6495574-B2 | THROMBOSIS DISEASES | BERLEX LABORATORIES, INC. | 2002-12-17 | — | — | US | disclosed |
| US-6492376-B2 | 3-((3,5-DIFLUORO-6-(3-(1-METHYLIMIDAZOLIN-2-YL)PHENOXY)-4 -(2,3 -DIHYDROXYPROPOXY)PYRIDIN-2-YL)OXY)-4-HYDROXYBENZAMIDINE, FOR EXAMPLE | BERLEX LABORATORIES, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20010044536-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | PHILLIPS GARY B (US) | 2001-11-22 | — | — | US | disclosed |
| US-20010044537-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2001-11-22 | — | — | US | disclosed |
| US-20010025108-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2001-09-27 | — | — | US | disclosed |
| US-20010023291-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2001-09-20 | — | — | US | disclosed |
| US-20010023292-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2001-09-20 | — | — | US | disclosed |
| EP-1131315-A1 | POLYHYDROXYLATED HETEROCYCLIC DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6262088-B1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | BERLEX LABORATORIES, INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000031068-A1 | POLYHYDROXYLATED HETEROCYCLIC DERIVATIVES AS ANTI-COAGULANTS | BERLEX LABORATORIES, INC. (DE) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023291-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, F8, SERPINC1 | PDCD1 3343/4885CD274 3393/4885MRGPRX4 2762/4885 |
| US-20010044536-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, SERPINC1, F11 | PDCD1 3466/4885CD274 3651/4885MRGPRX4 2982/4885 |
| US-20010044537-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, SERPINC1, F11 | PDCD1 3466/4885CD274 3651/4885MRGPRX4 2982/4885 |
| US-20030149040-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, SERPINC1, F8 | PDCD1 3377/4885CD274 3393/4885MRGPRX4 2887/4885 |
| US-20010025108-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, SERPINC1, F8 | PDCD1 3368/4885CD274 3158/4885MRGPRX4 3168/4885 |
| US-20010023292-A1 | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants | F2, SERPINC1, F8 | PDCD1 3418/4885CD274 3454/4885MRGPRX4 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.